Skip to main content
. Author manuscript; available in PMC: 2007 Aug 19.
Published in final edited form as: Br J Haematol. 2006 Jun;133(6):642–645. doi: 10.1111/j.1365-2141.2006.06094.x

Table I.

Overexpression of theVAV protooncogene product according to the type of haematological tumour analysed.

Positive†,‡
Disease type n* VAV overexpression VAV phosphorylation
CMD
 Polycythaemia vera 11 0† 0‡
 Essential thrombocythaemia 12 0 0
 Agnogenic myeloid metaplasia 3 0 0
 Chronic myeloid leukaemia 3 0 0
 Non-classificable MDS/CMD 3 0 0
B-ALL 10 0 0
B-NHL 15 2 2
B-CLL
 Normal FISH karyotype 33 7† 6‡
 13q deletion 14 10 8
 Chromosome 12 trisomy 6 1 0
 17p deletion 6 2 2
 11q deletion 2 1 1
*

Number of patients in the indicated disease group.

†

Number of positives for VAV overexpression

‡

Number of positives for VAV phosphorylation on the regulatory Y 174 residue, as determined by immunoblot analysis.

MDS/CMD, Myelodysplastic syndrome/chronic myeloproliferative disorder; CMD, Chronic myeloproliferative disease; B-ALL, B-cell acute lymphoblastic leukaemia; B-NHL, B-cell leukae-mic non-Hodgkin lymphoma; B-CLL, B-cell chronic lymphocytic leukaemia; FISH, Fluorescence in situ hybridization analysis.